• DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Neglected tropical diseases & neglected patients
paediatric-hiv icon

Paediatric HIV

Saving children’s lives by developing new treatments to meet their needs

Home > Neglected tropical diseases & neglected patients
paediatric-hiv icon

Paediatric HIV

Saving children’s lives by developing new treatments to meet their needs

  • Overview
  • Facts
  • Projects & achievements
  • Target product profile
  • Advocacy toolkit

We developed an easy-to-administer, strawberry-flavoured combination of four antiretroviral medicines to meet the needs of the youngest children, who are at the highest risk of dying without treatment. With regulatory review underway, our partnerships are working to ensure quick treatment roll-out for thousands of children in need.

The needs of children with HIV have long been neglected. While R&D efforts have succeeded in developing life-saving diagnosis and treatment innovations for adults, innovation for children lags far behind.

Until recently, the only treatments available for babies and kids were bitter-tasting, difficult to dose, and required refrigeration – making them unsuitable for children and their caregivers. Thankfully, new paediatric formulations are finally becoming available after decades of poor options. Our work is a key part of this revolution in paediatric HIV diagnosis and treatment.

Icon child
0 %
of children with HIV will die before their second birthday without treatment
Icon people in front of globe
0 million
children are living with HIV
Icon pills
0 %
children receive lifesaving treatment
SEE DISEASE FACTS
DOWNLOAD FACTSHEET

‘The initial treatment was difficult to administer because of their bitter taste. Many times, Emmanuel would spit the medication instead of swallowing.’

Pamela Akoth, stepmother of Emmanuel, living with HIV and treated at the Lea Toto Kariobangi site in Nairobi, Kenya.

What we have achieved

Our research is helping countries replace older, difficult–to–use, and sometimes ineffective formulations and scale up new, optimum treatments for young children. 

icon-treatments
Treatment Delivered

Super-booster therapy

New hope for children co-infected with HIV and TB. Drugs used to treat tuberculosis can interfere with HIV treatment, reducing its effectiveness. A successful study with our South African partners paved the way for better treatment for children living with both diseases.

What we are doing for children living with HIV

In order to help end the neglect of babies and young children with HIV, we have developed an easy-to-administer, strawberry-flavoured ‘4-in-1’ treatment called Quadrimune, together with the Indian company Cipla. But our engagement goes well beyond drug development alone. Through a series of partnerships, we are working to ensure improved treatments for kids are rolled out where they are needed most. 

DISEASE TARGET PRODUCT PROFILE
Registration & access

2-in-1 LPV/r pellets and ABC/3TC

One of the largest paediatric HIV cohorts in the world. Our implementation study with over 1,000 children in Kenya, Uganda, and Tanzania seeks to improve uptake of newer treatments for kids.

Clinical trials

4-in-1 (ABC/3TC/LPV/r)

A strawberry-flavoured, ‘4-in-1’ treatment for children. Quadrimune meets the treatment needs of the youngest children living with HIV. The combination of four antiretrovirals in easy-to-administer, heat-stable, strawberry-flavoured granules is now under US FDA review.

see all projects

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Is transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’re working to deliver a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Woman standing in front of her door house in a rural village in Sudan

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We’re conducting the world’s first trial for an alternative to current treatments, which are toxic and ineffective

Mother holding her baby in her arms smiling

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

Cutaneous leishmaniasis

Filaria: river blindness

Hepatitis C

Mycetoma

Paediatric HIV

Sleeping sickness

Visceral leishmaniasis

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi logo
Facebook-f Twitter Instagram Linkedin-in Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY